Yahoo Web Search

Search results

    • Biogen enters deal to acquire HI-Bio for $1.8bn

      Biogen enters deal to acquire HI-Bio for $1.8bn

      Pharmaceutical Technology via Yahoo Finance· 1 hour ago

      -Bio specialises in targeted treatments for severe immune-mediated diseases (IMDs). Its lead asset, felzartamab, is a fully human anti-CD38 monoclonal...